MUC16,CA125 Monoclonal antibody

MUC16,CA125 Monoclonal Antibody for IHC,ELISA

Host / Isotype

Mouse / IgG1









Cat no : 60261-1-Ig


CA 125, CA125, MUC 16, MUC16, Mucin 16

Tested Applications

Positive IHC detected inhuman ovary tumor tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Immunohistochemistry (IHC)IHC : 1:20-1:200
Sample-dependent, check data in validation data gallery

Published Applications

IHCSee 2 publications below

Product Information

60261-1-Ig targets MUC16,CA125 in IHC,ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen Peptide
Full Name mucin 16, cell surface associated
Calculated molecular weight 1519 kDa
GenBank accession numberNM_024690
Gene symbol MUC16
Gene ID (NCBI) 94025
Conjugate Unconjugated
Form Liquid
Purification Method Protein G purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

MUC16, also named as CA125, is thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. It is a serum marker that is used routinely in gynecologic practice to monitor patients with ovarian cancer. Most biochemical studies have concluded that MUC16 is a high molecular mass glycoprotein, although estimates of its size range from 200 to 2000 kDa with smaller “subunits” being described by some investigators. The antibody recognizes the C-term of MUC16.


Product Specific Protocols
IHC protocol for MUC16,CA125 antibody 60261-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Int J Oncol

Lewis antigen‑negative pancreatic cancer: An aggressive subgroup.

Authors - Chen Liu

Cancer Lett

MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.

Authors - Kun Fan